Martin Babler, Alumis CEO

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Alu­mis, an im­munol­o­gy drug de­vel­op­er on the cusp of Phase 3, will go pub­lic Fri­day in a small­er IPO than it orig­i­nal­ly pro­ject­ed.

The Bay …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.